openPR Logo
Press release

Global Companion Diagnostics Market, By Application(Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Melanoma), Technology(Immunohistochemistry, Real-time PCR, Gene Sequencing, FISH), and Geography - Trends, Analysis and Forecast till 2024

04-19-2017 10:00 AM CET | Health & Medicine

Press release from: Global Companion Diagnostics Market

Global Companion Diagnostics Market, By Application(Breast

Companion diagnostic (CDx) is a diagnostic tool used to determine the suitability of a drug therapy to the patient. It has become a critical part of targeted cancer therapy that allows for development of personalized therapy can be developed and administered to the patient. Whole blood samples, tissues samples, or buccal samples are collected and tested for diagnosis and identification of targeted disease biomarker. CDx is usually utilized in identifying genetic mutations and the health and treatment approach implications. In July 2016, the U.S. FDA released a draft guideline for development of a therapeutic product accompanying an IVD companion diagnostic. Companion diagnostics include Gleevec (imatinib mesylate) and BCR-ABL LDT and DAKO C-KIT PharmDx, Herceptin (trastuzumab) and DAKO Herceptest; and Nolvaldex (tamoxifen) and laboratory-developed estrogen receptor positive test.

Get Exclusive Discount on this CMI Report: https://www.coherentmarketinsights.com/insight/request-discount/109

Market Dynamics

Companion diagnostics are beneficial for pharmaceutical companies who face challenges with respect to high drug development cost, safety and outcome of clinical trials, and long product approval time. Companion diagnostics lowers development costs, improves time to market and enhances drug safety by enabling rapid identification of target biomarker and the most effective drug therapy. For patients, the technology provides better treatment outcomes and lower morbidity risk. Use of technologies such as PCR, immunohistochemistry, and gene sequencing has enabled accurate diagnosis and determination of targeted cancer therapy. As the CDx tests also aid in revealing the off-target effects of a drug along with identification of a molecular target, CDx have become and indispensable tool for oncologists.

Market Taxonomy

This report segments the global companion diagnostics market on the basis of application, technology, and geography. On the basis of application, the market is categorized into breast cancer, lung cancer, colorectal cancer, gastric cancer, melanoma, and others. On the basis of technology, the market is segmented into immunohistochemistry, real-time PCR, gene sequencing, Fluorescence in situ hybridization (FISH), and others. For comprehensive understanding of market dynamics, the global companion diagnostics market is analyzed across key geographical regions namely North America, Europe, Asia Pacific, Latin America, Africa, and Middle East. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Download Exclusive PDF Brochure of This Report : https://www.coherentmarketinsights.com/insight/request-sample/109

Key features of the study:

This report provides in-depth analysis of the companion diagnostics and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2016 – 2024, considering 2015 as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players

It profiles leading players in the global companion diagnostics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans

Key companies covered as a part of this study include Abbott Laboratories, Inc., Agilent Technologies, Inc., Danaher Corporation, GE Healthcare, Qiagen N.V., Roche Diagnostics, Myriad Genetics, Inc., bioMérieux SA, Illumina, Inc. and Siemens Healthcare

Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, technology upgrades, market expansion, and marketing tactics

Browse Global Strategic Business Report : https://www.coherentmarketinsights.com/market-insight/companion-diagnostics-market-109

The global companion diagnostics market report caters to various stakeholders in this industry, including investors, device manufacturers, distributors and suppliers for companion diagnostics, research and consulting firms, new entrants, and financial analysts

Various strategy matrices used in analyzing the companion diagnostics market would provide stakeholders vital inputs to make strategic decisions accordingly

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit Coherent Market Insights Blog @ https://blog.coherentmarketinsights.com/
Connect with us on LinkedIn @ https://www.linkedin.com/company/coherent-market-insights

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Companion Diagnostics Market, By Application(Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Melanoma), Technology(Immunohistochemistry, Real-time PCR, Gene Sequencing, FISH), and Geography - Trends, Analysis and Forecast till 2024 here

News-ID: 505885 • Views:

More Releases from Global Companion Diagnostics Market

GLOBAL COMPANION DIAGNOSTICS MARKET, BY APPLICATION(BREAST CANCER, LUNG CANCER, COLORECTAL CANCER, GASTRIC CANCER, MELANOMA), TECHNOLOGY(IMMUNOHISTOCHEMISTRY, REAL-TIME PCR, GENE SEQUENCING, FISH), AND GEOGRAPHY - TRENDS, ANALYSIS AND FORECAST TILL 2024
GLOBAL COMPANION DIAGNOSTICS MARKET, BY APPLICATION(BREAST CANCER, LUNG CANCER, …
Companion Diagnostics – Growth Companion for Personalized Medicine Personalized medicine is the new segment in discussion among healthcare experts around the globe. Also, encouragement from the regulatory bodies such as the FDA and EMEA in erms of providing a defined structure for companion diagnostic development is driving research activities in personalized medicine. Diagnosis at molecular level for each individual is of prime importance to identify the target biomarker before deciding the
Global Companion Diagnostics Market to Grow Globally
Global Companion Diagnostics Market to Grow Globally
Companion diagnostic (CDx) is a diagnostic tool used to determine the suitability of a drug therapy to the patient. It has become a critical part of targeted cancer therapy that allows for development of personalized therapy can be developed and administered to the patient. Whole blood samples, tissues samples, or buccal samples are collected and tested for diagnosis and identification of targeted disease biomarker. CDx is usually utilized in identifying
Global Companion Diagnostics Market, By Application(Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Melanoma), Technology(Immunohistochemistry, Real-time PCR, Gene Sequencing, FISH), and Geography - Trends, Analysis and Forecast till 2024
Global Companion Diagnostics Market, By Application(Breast Cancer, Lung Cancer, …
Companion Diagnostics – Growth Companion for Personalized Medicine Personalized medicine is the new segment in discussion among healthcare experts around the globe. Also, encouragement from the regulatory bodies such as the FDA and EMEA in erms of providing a defined structure for companion diagnostic development is driving research activities in personalized medicine. Diagnosis at molecular level for each individual is of prime importance to identify the target biomarker before deciding the
Global Companion Diagnostics Market, By Application(Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Melanoma), Technology(Immunohistochemistry, Real-time PCR, Gene Sequencing, FISH), and Geography - Trends, Analysis and Forecast till 2024
Global Companion Diagnostics Market, By Application(Breast Cancer, Lung Cancer, …
Companion diagnostic (CDx) is a diagnostic tool used to determine the suitability of a drug therapy to the patient. It has become a critical part of targeted cancer therapy that allows for development of personalized therapy can be developed and administered to the patient. Whole blood samples, tissues samples, or buccal samples are collected and tested for diagnosis and identification of targeted disease biomarker. CDx is usually utilized in identifying

All 5 Releases


More Releases for CDx

Companion Diagnostic (CDx) Market Outlook & Growth Prediction 2022 By Leading Pl …
Stratagem Market Insights recently published a research report titled, "Companion Diagnostic (CDx) Market - Increase in Demand and Opportunities 2022". The research report attempts to give a holistic overview of the Companion Diagnostic (CDx) market by keeping the information simple, relevant, accurate, and to the point. The research report highlights the inner and outer examination of the Companion Diagnostic (CDx) market. This intelligence report includes investigations based on Current scenarios,
Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market …
The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) report compiles the market information depending upon market development and growth factors, optimizing the growth path. In addition, it highlights the strategies and market share of the leading vendors in the particular market. The report follows a robust research methodology model that helps to make informed decisions. It obtains both qualitative and quantitative market information supported by primary research. The Pharmacogenomics Technology
Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market …
The market report delivers an all-inclusive analysis of the market structure along with a forecast of the various segments and sub-segments of the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) industry. This wide-ranging market research report acts as a backbone for the success of business in any niche. The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market survey report has been prepared by conducting market research in a
Pharmacogenomics Technology (Theranostics & Cdx) Market 2021 Analysis by Size, S …
This comprehensive Report on the Pharmacogenomics Technology (Theranostics & Cdx) Market provides real information about the statistics and state of the global and regional market. Its scope study extends from the market situation to comparative pricing between the main players, spending in specific market areas, and profits. It represents a comprehensive and succinct analysis report of the main competitor and price statistics with a view to helping beginners establish their
Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Mark …
This report studies the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market by companies, region, type and end-use industry. Get Sample Copy of This Report @ https://www.researchtrades.com/request-sample/1644663 In 2017, the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market size was million US$ and it is expected to reach million US$ by the end of 2025,
Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Sale …
This report studies the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market, analyzes and researches the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like Qiagen NV GE Healthcare Agilent Technologies F Hoffman La Roche Foundation Medicine Thermo Fisher Scientific Inc. Leica Biosystems Nussloch GmBH Pfizer Get the sample copy of report : https://www.marketresearchreports.biz/sample/sample/1486733 Market segment by Regions/Countries, this report covers United States EU Japan China India Southeast